Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Pink Sheet Podcast: Leqembi Spending, Woodcock’s Next Act, Pneumococcal Vaccine Development

Executive Summary

Pink Sheet editors discuss Medicare spending projections for the Alzheimer’s treatment Leqembi, Janet Woodcock’s new post-FDA role, and ongoing preparations for new pneumococcal vaccines that will reach the market soon.

Pink Sheet Executive Editor Derrick Gingery, Senior Editor Cathy Kelly, Managing Editor Bridget Silverman and Editor in Chief Nielsen Hobbs consider the questions about a US Centers for Medicare and Medicaid Services' estimate of upcoming spending on Eisai Co., Ltd. and Biogen, Inc.’s Alzheimer’s treatment Leqembi (lecanemab-irmb) (:28), the new role for former US Food and Drug Administration Principal Deputy Commissioner Janet Woodcock (12:28), and the US Centers for Disease Control and Prevention’s ongoing preparation for new pneumococcal vaccines that are nearing market entry (17:28).

More On These Topics From The Pink Sheet

This and other podcasts are available on the Pink Sheet podcast page, as well as the Citeline channel on Apple Podcasts, Google Podcasts, SoundCloud, TuneIn and Spotify Podcasts, and via smart speakers if one of these platforms has been set up as your default podcast provider.



Related Companies

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts